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ABSTRACT 
 
Stem cells are the foundation stones upon which the entire developmental opera is 
enacted and the basis of cellular differentiation and functional specialization is laid down. The 
most important contributor in this act are the four core transcriptional regulators which 
stringently control the gene expression system to script a transcriptional program that maintains 
pluripotency and also guides cellular differentiation for functional phenotypes. The resultant 
transcriptional outcome is determined by epigenetic machinery. This system is also responsible 
for generating cancer stem cells which cause tumor resistance and recurrence. The present 
project is designed to study the epigenetic regulatory mechanism behind gene expression status 
of pluripotency genes –OCT4, SOX2, NANOG and KLF4 after treatment with various 
epigenetic modulators that affect cell growth and survival in breast cancer. The project will open 
up avenues for better management of caner and provide strategies for efficient cancer treatment. 
 
Keywords: Stem Cells, Pluripotency, Epigenetics, Transcription Factors, Breast Cancer 
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INTRODUCTION 
 
The developmental transition of a single celled zygote into a multifunctional organism 
involves many translations of the genetic code, extensive manipulation of the epigenetic 
information and dynamic interactions between various nuclear remodelers and chromatin 
architectures to reorganize the genomic information into cellular identity. The entire 
developmental opera is orchestrated by stem cells that play a crucial part during transition from 
totipotency to functional specialization in the form of unipotency. However, the bulk of this 
burden is heaved upon transcription factors that work stringently to turn ON or OFF the 
expression of downstream genes in response to myriad developmental cues in different 
biological settings. Coordinated transcription factor networks function as master regulatory 
mechanisms guarding stem cell pluripotency and effectively directing cellular differentiation. 
Among the host of transcription factors involved, OCT4, SOX2, NANOG and KLF4 are 
considered as the master regulators as they efficiently balance the equilibrium between stem cell 
self-renewal, proliferation and differentiation. These four core factors maintain the 
undifferentiated state of pluripotent cells by activating the genes necessary for stem cell survival 
and proliferation while simultaneously repressing the genes that are responsible for lineage-
commitment and speciation. 
In recent years, epigenetic modifications have been increasingly acknowledged as 
eminent mediators in the process of lineage-commitment, reprogramming and differentiation. 
The epigenetic manipulations are responsible for maintaining stem cell pluripotency, creating 
tissue-specific gene expression profiles and ‘locking’ differentiated cells into committed cell 
types without changing the underlying DNA sequence. The most prominent epigenetic agents 
participating in this scheme include DNA methylation and covalent post-translational Histone 
modifications. Transient histone modifications of the lineage-committed genes result in a short 
term 'poised state' which is followed by long-term or permanent repression of pluripotency genes 
by DNA methylation, nucleosomal rearrangement and higher-order chromatin re-structuring that 
result in onset of differentiation. This epigenetic choreography of the stem cell fate for a lineage-
dependent identity is achieved via co-ordination among numerous enzymatic players responsible 
for deposition (writers) and removal (erasers) of the epigenetic tags, as well as protein complexes 
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that recognize these modifications (readers) and the core transcriptional factors -- OCT4, SOX2, 
NANOG and KLF4. However, it is unclear whether these key transcription factors result in a 
lineage-restricted epigenetic program or whether pre-imposed epigenetic restrictions decide the 
course of action of these factors to determine lineage potential and confer specialized functional 
identity to a cell.  
Crosstalk between pluripotency factors and epigenetic modifiers is one of the 
fundamental forces behind the pluripotent state of stem cells and their gradual progression 
towards specialized cellular identity. Given the strategic importance of both of these regulatory 
agents in maintaining pluripotency, it is obvious that deregulation of the stem cell pluripotency 
network may contribute to malignant transformation of adult stem cells resulting in cancer stem 
cells (CSCs). The self-renewing CSCs originate from the same stem cell pool as the ESCs and 
share many key biological properties; chief among them being self-renewal and differentiation 
ability. Yet, switching of the ESCs into CSCs is arbitrated mostly by epigenetic changes in the 
genome of stem cells and facilitated by core reprogramming factors such as OCT4, SOX2, 
NANOG and KLF4. Keeping in mind the above-mentioned fact, this project has been designed 
to investigate the epigenetic regulatory network controlling the expression of pluripotency 
inducing factors -- OCT4, SOX2, NANOG and KLF4 in breast cancer. A comparative analysis 
of the gene expression profile of these four transcription factors after treatment with various 
epigenetic modulators will be done to corroborate the presence of pluripotency-associated 
markers to the inherent tumorigenicity in various human breast cancer cell lines. The project will 
be helpful in understanding the role of these transcription factors in aiding the CSCs to generate 
therapy resistance. Moreover, deciphering the epigenetic regulatory landscape behind pluripotent 
chromatin state may help to explain the cause of differential response of reprogrammed cells to 
the ectopic expression of OCT4, SOX2, NANOG and KLF4. The project will also provide 
opportunities to devise novel strategies for inhibiting CSCs by targeting their epigenetic 
regulatory circuit and effectively preventing cancer relapse and regression. As researchers and 
oncologists are struggling to find a successful treatment approach for metastatically aggressive 
malignancies, decoding unravelling the epigenetic machinery controlling transcriptional network 
of a cancer cell will be one step forward in this endeavour. 
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REVIEW OF LITERATURE 
 
Stem Cells – The veritable mine of progenitor cells: 
 Stem cells are considered to be progenitor of more than 200 cell types present in adult body. 
All stem cells are undifferentiated cells that retain the ability to divide throughout life and give 
rise to highly specialized and committed cells (Avasthi et al., 2008). Stem cells can be off 
different types depending upon their potency; e.g. totipotent, pluripotent, multipotent or 
unipotent. Totipotent stem cells are produced upon fusion of an egg and sperm and can give rise 
to every cell type present in a multicellular organism. Pluripotent stem cells originate from the 
totipotent cells and can differentiate into the 3 embryonic germ layers -- endoderm, mesoderm 
and ectoderm. Multipotent stem cells can produce cells of a particular lineage e.g. hematopoietic 
stem cells differentiate into RBCs, WBCs, platelets etc. Finally, unipotent stem cells are 
functionally specialized and capable of differentiating into highly committed cells of the adult 
body. Thus, stem cell reservoir in an organism is a very valuable mine of progenitor cells 
continuously replinshing the cellular pool in different biological settings (Kar et al., 2014).  
 
Stem Cells and Transcriptional Control of Differentiation: 
 The ability of the stem cells to continuously self-renew and differentiate indefinitely is 
supported by a well-co-ordinated network of transcription factors that smoothly manoeuvre the 
transition between differential gene expression states to generate functionally specific and 
specialized cellular phenotypes (Egli et al., 2008). This is clearly substantiated by the fact that 
pluripotent stem cells (PSCs) can be derived from mouse embryonic fibroblasts by inducing 
transcription factors expression (Zhao et al., 2012). By the over-expression of a set of core 
transcription factors –OCT4, SOX2, NANOG and KLF4, adult differentiated cells can be 
reverted back to produce Induced pluripotent stem (iPS) cells (Patra et al., 2011;Tai et al, 2005; 
Visvader and Lindeman , 2008).  These four factors form the central command station which 
manipulates the stem cell genome to formulate different combitorial gene expression programs 
and result in widely different cellular phenotypes.  
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Epigenetic regulation of Transcription Factors control stem cell transcriptional fate: 
In recent years, epigenetic modifications have been increasingly credited for defining the 
cellular reprogramming status and deciding the stem cell identity. Alongside DNA methylation 
and bivalent Histone modifications also contribute to this mechanism (Jenuwein and Allis, 2001; 
Santos and Dean, 2004). An active configuration of the chromatin architecture is generally 
responsible for establishment of pluripotent state. OCT4 is dynamically regulated by differential 
methylation levels during different phases of embryogenesis and consequently plays an essential 
role in differentiation. Bivalent Histone domains containing a large region of H3K27 
trimethylation harboring a smaller region of H3K4 trimethylation are frequently associated with 
developmentally regulated transcription factors that are expressed at low levels. Upon 
differentiation, most of the bivalent domains become either H3K4 methylated or H3H27 
methylated, consistent with associated changes in gene expression. ES cell differentiation is 
associated with a decrease in global levels of active histone marks, such as acetylated histone H3 
and H4 (Lee et al, 2004; Meshorer et al., 2006). In addition to histone tags, the chromatin 
architecture assumes a favourable state for maintenance of pluripotency. Such a highly dynamic 
and transcriptionally permissive chromatin environment may facilitate rapid transcriptional 
profile alternations upon differentiation and allow various transcriptional profiles to be 
established. 
Pluripotency Factors and Cancer stem cell Hypothesis: 
It is now a generally accepted idea that a sub-population of stem cells called cancer stem 
cells (CSCs) are found in a tumor niche which are capable of proliferating the tumor as well as 
developing high resistance against conventional chemo and radiation therapies. This unique 
population of cells is responsible for promoting metastasis and help in recurrence of tumor after 
therapy (Chen et al., 2008). CSCs may be considered as descendants form the same stem cell 
niche as their normal embryonic stem cells; however the ugly transformation into perpetuators of 
malignancy is mainly decided by epigenetic alteration of the transcriptional circuitry in ES cells 
(Guo et al., 2006). Transcription factors—OCT4, SOX2, NANOG and KLF4 that regulate ESC 
fate also operate in renewing cancer cells (Chang et al., 2008).  The aberrant expression of OCT 
3/4, NANOG, SOX-2 and KLF4 has been shown in numerous types of tumors and it is possible 
that this may contribute to the neoplastic process and play a role in cancer development.  
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OCT3/4 is highly expressed in ESCs, carcinoma cells and oocytes (Matin et al., 2004; Okita et 
al., 2007; Park et al., 2008). Previous studies of NANOG in tumors have suggested its 
tumorigenic potential and regulation of tumor development in human osteosarcoma. A number 
of links have also been identified between SOX-2 transcription factors and human cancers (Dong 
et al., 2004). SOX-2 expression has been observed in embryonal carcinoma, teratoma, lung, 
pancreactic and gastric adenocarcinoma. It is seen that KLF4 has a dual role in tumorigenesis, 
while in some cancers it is highly down-regulated such as in gastric, colorectal, bladder and 
prostate cancers (Wei et al., 2006; Ohnishi et al., 2003). On the other hand, elevated KLF4 levels 
have also been linked to cancer. It was found that KLF4 is overexpressed in 70% mammary 
carcinomas and most squamous cell carcinomas of the oropharynx. Breast cancer is the most 
frequent cancer among females, being a heterogeneous disease, with distinct morphologies, 
metastatic behavior and therapeutic responses. The expression of OCT3/4, NANOG and SOX2 
in human breast cancer cell lines MDA-MB-23 is high. In this study we are analyzing the effect 
of AZA (inhibitor of DNMT), TSA, EGCG, Thymoquinone, SFN Curcumin, SAM (co-factor in 
the methylation reaction) and SAH on the expression of NANOG, OCT4, SOX2 and KLF4 in 
breast cancer. 
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OBJECTIVES OF THE PROJECT 
 
1. Study of the gene expression status of the different pluripotency genes -- SOX2, OCT4, 
NANOG and Klf4 in MDA-MB-231 breast cancer cell lines. 
 
2. Study of the effect of various epigenetic modulators such as AZA (inhibitor of DNMT), 
SAM (co-factor in the methylation reaction), TSA and SFN (Histone deacetylase 
inhibitors), EGCG and Curcumin (Natural HH antagonists) on the survival and growth 
characteristics of MDA-MB-231 breast cancer cells.  
 
3. Comparative analysis of the effect of various epigenetic modulators on the expression of 
the different pluripotency genes after treatment.  
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MATERIALS AND METHODS 
 
1. In vitro cell culture: 
Human breast carcinoma cell line MDA-MB-231 was cultured and maintained in Dulbecco’s 
Modified Eagle’s Medium (DMEM, Invitrogen) supplemented with 10% (v/v) Fetal Bovine 
Serum (FBS, Invitrogen) and 100 IU/mL penicillin and 0.1 mg/mL streptomycin in a 
humified atmosphere of 5% CO2 at 37°C. 
 
2. Treatment with epigenetic drugs –AZA, SAM, TSA, SFN, EGCG, Curcumin: 
Stock solutions of AZA, TSA, SFN, EGCG and Curcumin (Sigma) were prepared in 
dimethylsulphoxide (DMSO, Sigma) whereas SAM (Sigma) was dissolved in milli-Q water. 
Cells were harvested by trypsinization and cell number was counted by haemocytometer. For 
determining the concentration of drug that inhibited cell proliferation by 50% (IC50), 5 X 10
3
 
cells per well were seeded in 96-well microtiter plate and after 24 h incubation, were treated 
with the epigenetic modulators at different concentrations (Table1) mixed in DMEM 
supplemented with 5% FBS. Control cells were treated with DMSO only. The cells were then 
incubated for 24 h. 
Table 1: Different concentrations of the various epigenetic drugs considered for MTT assay 
Drugs Concentrations 
AZA 5, 7.5, 10, 12.5, 15, 17.5, 20, 25 μM 
SAM 5, 7.5, 10, 12.5, 15, 17.5, 20, 25 μM 
TSA 50, 100, 150, 200, 300, 350, 400 nM 
SFN 5, 7.5, 10, 12.5, 15, 17.5, 20, 25 μM 
EGCG 50, 100, 150, 200, 300, 350, 400 μM  
Curcumin 10, 20, 30, 40, 50, 60, 70 μM 
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3. Cell Viability Analysis by colometric MTT Assay:  
The effect of the epigenetic drugs on cellular proliferation was assessed by 3-(4, 5-
Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT, Sigma) assay, using 
standard protocol. The MTT assay is based on the observation that mitochondria in living 
cells can catalyze MTT molecules to a colorimetrically detectable dye. Briefly, the drug-
treated cells in each of the 96 wells were washed twice with PBS. 0.8 mg/mL MTT solution 
was prepared from stock MTT solution (5 mg/mL PBS, pH 7.2). 100 μL MTT solution was 
added to each well and incubated at 37º C for 4 h in dark. The supernatant was removed and 
100 µL of DMSO was added into each well to dissolve the formazan crystals. The 
absorbance was measured at 570 nm and results were expressed as the mean of three 
replicates as a percentage of control (taken as 100%).The extent of cytotoxicity was defined 
as the relative reduction of the optical density (OD), which correlated to the amount of viable 
cells in relation to cell control (100%). The absorbance was plotted in a graph and the IC50 
was calculated accordingly to decide the optimum dosage of the drugs for further studies. 
 
4.  Chromatin condensation analysis by Hoechst staining:  
After treatment with epigenetic modulators at the IC50 concentration, cells were stained with 
Hoechst 33342 stain (1 mg/ml, Invitrogen) followed by incubation for 10 mins at 37
o 
C. 
Images were taken under UV filter using Epi-fluorescent Microscope (Olympus IX71) at 400 
X magnification with an excitation wavelength of 355-366 nm and an emission wavelength 
of 465-480 nm. Condensed nuclei were counted against total number of nuclei in the field, 
and the percentage of apoptotic nuclei were calculated and plotted graphically.  
 
5. Scratch and Migration Assay: 
The effect of various epigenetic modulators on the wound healing and cell migration was 
assessed by scratch and migration assay. Approximately 10
6 
cells were seeded onto 6-well 
plates and incubated for 24 h. A scratch was done with the help of a sterile tip, media was 
removed and then the cells were washed twice with PBS and then treated with the IC50 
values of the various epigenetic drugs. The cells were then incubated for 24 h and then 
images were taken using Epi-fluorescent Microscope (Olympus IX71) at 10X magnification. 
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6. Extraction of Total RNA:  
MDA-MB-231 cell lines were treated with sub lethal dosages of AZA (15 μM), SAM (15 
μM) TSA (150 nM), SFN (10 μM), EGCG (250 μM) and Curcumin (25 μM) for 24 and 48 h. 
After treatment for the required time, total RNA was extracted using the Trizol (Sigma) 
reagent according to the manufacturer’s instructions. The drug treated cells (5-10 X 106 cells) 
were washed with 1 ml ice cold PBS, then trypsinized and then treated with 1 ml Trizol. 0.2 
ml of chloroform (Sigma) (0.2 ml per 1 ml of TRI Reagent) was added to the tubes, shaken 
vigorously for 30 seconds by hand/vortex mixer and incubated at RT for 10 mins. The 
samples were centrifuged at 12,000 X g for 15 mins at 4° C. Following centrifugation, the 
mixture separates into lower red, phenol-chloroform phase, an interphase, and a colorless 
upper aqueous phase containing the RNA. The upper aqueous phase was removed without 
disturbing the interphase and collected in a fresh tube. 0.5 ml isopropyl alcohol (Sigma) per 1 
ml of TRI Reagent was added to the tubes. The tubes were then incubated at RT for 10 
minutes and then centrifuged at not more than 12,000 x g for 10 minutes at 4° C. The 
supernatant was removed completely. The RNA precipitate, often invisible before 
centrifugation, forms a gel-like pellet on the side and bottom of the tube. The pellet was 
washed with 1ml of 75% ethanol per 1 ml of TRI Reagent. The samples were mixed by 
vortexing and centrifuged at no more than 7,500 x g for 5 minutes 4° C. The pellet was air-
dried by keeping the RNA pellet containing tube opened in working bench for 15 mins. The 
RNA was dissolved in 50 μl DEPC-treated water by passing solution a few times through a 
pipette tip. The RNA was stored at - 20° C for further use or immediately processed for 
cDNA synthesis.  
 
7. Quantitative Estimation of RNA Concentration by Spectrophotometric Analysis:  
The concentration of the extracted total RNA was quantified by measuring the absorbance at 
260 nm in a spectrophotometer (ELICO, BL 200 Bio Spectrophotometer, double beam) and 
calculated by using the formula as given below:  
Total RNA (μg /ml) = OD260 × 40 × Dilution factor. 
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8. First strand cDNA synthesis:  
Total RNA (2 μg) was used for first strand cDNA synthesis by reverse transcription using 
RevertAidTM First Strand cDNA Synthesis Kit (Fermentas) in a thermocycler (Biorad). The 
RNA was incubated with 1 μl of oligo (dT)18 primers (100 μM, 0.2 μg/μl) and 12 μl of 
nuclease-free water at 65º C for 5 mins. The reaction was cooled on ice to allow the primers 
to anneal to the RNA, then spun down and placed on ice again after which the following 
components were added to the reaction in order; 4 μl of 5X Reaction Buffer, 1 μl of 
RibolockTM RNase inhibitor (20 U/μl), 2 μl of 10 mM dNTPs and 1.0 μL of RevertAidTM 
M-MuLV-Reverse Transcriptase (200 U/μl). The reagents were gently mixed and incubated 
for 1 h at 42º C. Heating at 70º C for 5 mins terminated the reaction and the synthesized 
cDNA was stored at –20º C for further use.  
 
9. Gene-specific semi-quantitative PCR for amplification of the desired genes:  
The PCR reaction mixtures, in a 25 μl volume, contained 17 μl of dH2O (Sigma), 2.5 μl of 
1X PCR buffer (Sigma), 0.5 μl of dNTP (0.2 mM, Sigma), 1.5 μl of MgCl2 (1.5 mM, 
Sigma), 0.5 μl each of the forward and reverse primers (0.2 μM, Sigma) of OCT4, SOX2, 
NANOG, KLF4, 0.5 μl Taq DNA-polymerase (1U/μl, Himedia). 2 μl of each cDNA sample 
was added. PCR amplifications were performed in a thermal cycler (Biorad) by initial 
denaturation at 94° C for 1 min, followed by 30 cycles of denaturation at 94° C for 20 secs, 
annealing at 58 ° C for 20 secs, and extension at 72° C for 30 secs, followed by an final 
extension step at 72° C for 5 mins. The constitutively expressed housekeeping gene, β-actin 
was used as a positive control to ensure high quality. RT-PCR products were then analyzed 
by 1% agarose gel electrophoresis containing ethidium bromide (0.05%). The primer 
sequences for the PCR reaction are shown in Table 2. 
 
10. Relative Gene Expression Analysis after drug treatment by Real-Time PCR: 
Quantitative estimation of the expression of the MBD genes after drug treatment was done 
via real-time PCR analysis. qRT-PCR was performed using cDNA prepared from 1μg of 
total RNA prepared using RevertAid First Strand cDNA Synthesis Kit (Thermo Scientific) 
and SYBR
®
 Green JumpStart™ Taq ReadyMix (Sigma) in the Realplex4Eppendorf system. 
The mRNA level was normalized to β-actin. The primer sequences are provided in Table 2. 
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Table 2: List of sequence and product length of the Real-Time PCR Primers 
Gene Primer sequence Tm Product 
NANOG 
F 5’--TCCTCCTCTTCCTCTATACTAAC—3’ 55.50 
112 bp 
R 5’-- CCCACAATCACAGGCATAG—3’ 55.66 
OCT4 
F 5’—AGCAAAACCCGGAGGAGT—3’ 58.42 
114 bp 
R 5’ – CCACATCGGCCTGTGTATATC—3’ 58.31 
SOX2 
F 5’-- GGAAATGGAGGGGTGCAAAAGAGG--3’ 65.81 
150 bp 
R 5’-TTGCGTGAGTGTGGATGGGATTGGTG-3’ 67.41 
KLF4 
F 5’—ACCCACACTTGTGATTACGC–3’ 58.48 
172 bp 
R 5’—CCGTGTGTTTACGGTAGTGC--3’ 59.21 
β-ACTIN 
F 5’- CTGGAACGGTGAAGGTGACA -3’ 58.12 
140 bp 
R 5’- AAGGGACTTCCTGTAACAACGCA -3’ 58.35 
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RESULTS AND DISCUSSION 
 
1. Cell Viability Analyses by colometric MTT Assay 
Epigenetic modulators inhibit cell growth in highly metastatic breast cancer cell line 
MDA-MB-231 in dose and time-dependent manner. 
 
The effect of the various epigenetic modulators -- AZA, SAM, TSA, SFN, EGCG and 
CR on the cell viability after 24 h and 48 h treatment was assessed by colorimetric MTT assay. 
The different modulators have their own distinct effect on cell viability at different 
concentrations in different time intervals. The results obtained from MTT assay are given below 
(Fig.1). 
       
Figure 1(a): The effect of different concentrations of DNMT modulators – AZA and SAM after 24 & 48 h. 
  
Figure 1(b): The effect of different concentrations of HDAC inhibitors –TSA and SFN after 24 & 48 h. 
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Figure 1(c): The effect of different concentrations of Natural HH antagonists – EGCG & CR after 24 & 48 h. 
 
In general, cell survival levels declined progressively with increasing doses and 
increasing time-periods for all the epigenetic drugs (Fig. 1(a, b, c)). From this assay, IC50 values 
i.e. the concentration of drug which results in 50% cell viability for MDA-MB-231 cells is 
determined as follows (Table 3). 
Table 3: IC50 concentrations of all the epigenetic modulators used against MDA-MB-231 
Drug IC50 Concentration 
AZA 15 μM 
SAM 15 μM 
TSA 150 nM 
SFN 10 μM 
EGCG 250 μM 
Curcumin 25 μM 
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2. Chromatin condensation analysis after drug treatment by Hoechst staining  
Epigenetic modulators promote apoptotic cell death in MDA-MB-231 breast cancer cells. 
 
Nuclear chromatin condensation analysis drug treated MDA-MB-231 cells by Hoechst 
staining was performed to study the cytotoxic effect of the epigenetic modulators on the MDA-
MB-231 cells. MDA-MB-231 cells were treated with IC50 concentration of the epigenetic drugs 
for 24 and 48 h to study their effect on cell cycle and cell growth. It is observed that all the 
epigenetic modulators promote apoptotic cell death in MDA-MB-231 cells as is evident from 
increased chromatin condensation which is a distinct characteristic of apoptotic cells (Fig. 2, 
panel I). The results of Hoechst staining assay are given below (Fig. 2). 
 
 Figure 2(a): Nuclear chromatin condensation in treated MDA-MB-231 cells after 24 h.  
Panel [I] representative images of Hoechst 33342 stained nuclei,  
Panel [II] percentage of condensed nuclei represented graphically.  
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Figure 2(b): Nuclear chromatin condensation in treated MDA-MB-231cells after 48 h.  
 
During apoptosis, the chromatin becomes inert, highly condensed, undergoes 
fragmentation and gets packaged into apoptotic bodies. The morphological changes induced by 
apoptosis can be visually detected by the blue-fluorescent Hoechst 33342 dye which brightly 
stains the highly condensed, dense chromatin of apoptotic cells in comparison to the chromatin 
of non-apoptotic cells. After treatment with the epigenetic modulators at specific 
concentrations—AZA (15 μM), SAM (15 μM), TSA (150 nM), SFN (10 μM), EGCG (250 μM) 
and CR (25 μM), the percentage of condensed nuclei are found to be 28.36%, 18.73%, 48.45%, 
53.46%, 21.34% and 27.87% respectively for 24 h (Fig. 2(a), Panel II) and 29.31%, 22.67%, 
54.23%, 58.34%, 32.45% and 42.67% for 48 h whereas the control cells exhibit 6.94% 
condensed nuclei (Fig. 2(b), Panel II). The percentage of condensed nuclei is highest in TSA and 
SFN treated cells, TSA and SFN are seen to be highly effective in inducing apoptosis in MDA-
MB-231 breast cancer cells.  
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3. Flow Cytometry Analysis of the effects of epigenetic drugs on cell cycle (FACS)  
      Epigenetic modulators induce G2-M arrest and apoptosis in MCF-7 and MDA-MB-231 cells. 
In order to study the effect of the epigenetic modulators on the cell cycle and cell growth, 
flow cytometry based cell cycle analysis of MDA-MB-231 cells after treatment for 24and 48 h 
with the different epigenetic modulators was performed. There is an alteration in the cell cycle 
distributions in the cell population with increasing time-interval (Fig. 3 (a, b)). After 24 h, 
percentage of G1, S, G2/M and apoptotic cells is 38.2%, 15.7%, 7.6% and 6.5% respectively for 
untreated control cells. After treatment with AZA (15 μM), the percentage of G1, S, G2/M and 
apoptotic cells is found to be 29.3%, 3.1%, 11.4% and 23.5% respectively. After treatment with 
SAM (15 μM), the percentage of G1, S, G2/M and apoptotic cells is found to be 18.5%, 13.3%, 
9.3% and 6.9% respectively. Similarly, for TSA (150 nM) treatment, the percentage of G1, S, 
G2/M and apoptotic cells is observed to be 16.3%, 5.4%, 9.9% and 39.3% respectively w.r.t 
untreated cells. The percentage of G1, S, G2/M and apoptotic cells after treatment with SFN (10 
μM) is seen to be 31.2%, 16.3%, 12.9% and 42.7% respectively w.r.t untreated cells. After 
treatment with EGCG (250 μM), 25.7%, 11.1%, 4.4% and 22.7% cells composed the G1, S, G2/M 
and apoptotic cell population. In case of Curcumin (25 μM) treatment, 39.6% of cells in G1 
phase, 9.6% of cells in S phase, 22.7% of cells in G2/M and 27.3% of apoptotic cells were 
reported.  
 
Figure 3(a): Cell cycle distribution of MDA-MB-231 cells  after treatment with  
different epigentic modulators for 24 h.  
18 | P a g e  
 
The cell population was also assessed after 48 h. In case of controls cells, the percentage 
of G1, S, G2/M and apoptotic cell population were found to be 11.2%, 5.7%, 3.6% and 12.5% 
respectively. After treatment with AZA (15 μM), the percentage of G1, S, G2/M and apoptotic 
cell population were seen to be 13.3%, 5.1%, 7.4% and 26.5% respectively. In case of SAM (15 
μM), the population of G1, S, G2/M and apoptotic cells is found to be 18.5%, 3.3%, 7.3% and 
8.9% respectively. For TSA (150 nM), the populations were 14.3%, 6.4%, 3.9% and 40.3% 
respectively w.r.t untreated cells. In case of SFN treatment, 13.2%, 8.3%, 5.9% and 43.7% of 
cells were found in G1, S, G2/M and apoptotic stage respectively w.r.t untreated cells. After 
EGCG (250 μM) treatment, the percentage of G1, S, G2/M and apoptotic cell population were 
found to be 16.7%, 6.1%, 5.4% and 24.2%. After treatment with Curcumin (25 μM), 15.7%, 
6.1%, 9.4% and 29.7% cells composed G1, S, G2/M and apoptotic cell population.  
 
Figure 3(b): Cell cycle distribution of MDA-MB-231 cells after treatment with  
different epigentic modulators for 48 h. 
 
From these observations, it is clear that the cell cycle distribution is affected by different 
epigenetic modulators in a time-dependent manner as is evident from increase in apoptotic 
population after 48 h w.r.t 24 h treatment. In general, there is a decrease in G1, S and G2/M 
population with increase in apoptotic cells. In case of SFN treatment, high percentage of 
apoptotic cells are seen, indicating that SFN is potentially effective in inducing apoptosis. TSA, 
EGCG and Curcumin treated cells also exhibit high apoptotic population. 
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4. Scratch and Migration Assay after drug treatment 
Epigenetic modulators affect wound healing ability of MDA-MB-231 cells in a time. 
 
The wound healing and cell migratory ability of MDA-MB-231 cells were assessed after 
treatment with epigenetic modulators by scratch assay. The cells were treated with IC50 
concentration of the epigenetic drugs for 24h to study their effect on cancer cell motility. It is 
observed that the wound healing ability is higher after 48 h in comparison to 24 h. MDA-MB-
231 is a highly metastatic cell line with high level of cell migration; hence after treatment the cell 
migration is assessed and is seen that TSA, SFN and CR treated cells show the least migration, 
whereas SAM, EGCG and AZA treated cells comparatively higher migration. The results of 
scratch assay are given below (Fig. 4). 
 
Figure 4: Microscopic images showing cell migration and wound healing in MDA MB-231 cells after different 
with various epigentic drugs for 24 h. 
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5. Relative Gene Expression Analysis after drug treatment by RT-PCR  
             In general, there is over-expression of all the pluripotency genes.  OCT4 and NANOG 
show differential expression after treatment with epigenetic drugs where the expression of SOX2 
and KLF4 shows slight variations. 
 
 
Figure 5(a): Relative fold change in OCT4 expression w.r.t β-actin in variously treated breast cancer cells  
 
Figure 5(b): Relative fold change in SOX2 expression w.r.t β-actin in variously treated breast cancer cells. 
21 | P a g e  
 
  
Figure 5(c): Relative fold change in NANOG expression w.r.t β-actin in variously treated breast cancer cells  
 
Figure 5(d): Relative fold change in KLF4 expression w.r.t β-actin in variously treated breast cancer cells  
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CONCLUSION 
In this study, the effect of different epigenetic drugs such as AZA, TSA, SFN, EGCG, 
Curcumin and SAM on the expression of different pluripotency related genes has been 
investigated. In vitro experiments showed that these epigenetic drugs affected the cell viability in 
a dose and time different manner. With increasing concentration of drugs and higher time interval 
of drug treatment, cells showed drastic decrease in cell viability and increased rates of apoptosis, 
indicating that these drugs affect cell growth. Scratch and Migration Assay shows that TSA, SFN 
and CR show the least wound healing ability, hence are highly effective drug against cancer 
cells. In FACS analysis, it was observed that TSA and SFN treated cells showed the highest rates 
of apoptosis, which indicates that these inhibitors are effective against cancer cells. The relative 
gene expression analysis showed that the level of expression of the four different pluripotency 
genes according to the type of drug treatment. While OCT4 and NANOG showed least 
expression in SFN, TSA and curcumin treated cells, the highest expression was observed in SAM 
and AZA treated cells. Thus, it is seen that HDAC inhibitors affect the gene expression as well as 
the cell growth and viability of breast cancer cells. Further studies on protein expression in drug 
treated cells will help to substantiate these observations. This study will provide a means to 
restrict pluripotency transcription factors and help in silencing of pluripotency genes. The turning 
on of these genes may be an efficient means to counteract malignant transformation; hence these 
pluripotency genes can be regarded as novel prognostic targets for cancer therapy.  
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